Aortic eNOS expression and phosphorylation in Apo-E knockout mice: Differing effects of rapamycin and simvastatin

Surgery

Volumn 136, Issue 2, 2004, Pages 323-328

  Naoum, Joseph J ^a   Zhang, Shu ^a   Woodside, Kenneth J ^a   Song, Wei ^a   Guo, Qian ^a   Belalcazar, Ligia M ^a   Hunter, Glenn C ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; RAPAMYCIN; SIMVASTATIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD SAMPLING; CHOLESTEROL DIET; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; AORTA; APOLIPOPROTEINS E; CAVEOLIN 1; CAVEOLINS; CHOLESTEROL; ENDOTHELIAL CELLS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; SIMVASTATIN; SIROLIMUS;

EID: 3843150632     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2004.05.007     Document Type: Article

References (19)

1. Forstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 23:1994;1121-1131
2. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1995;1319-1330
3. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 100:1997;2153-2157
4. Marx J. Caveolae: a once-elusive structure gets some respect. Science. 294:2001;1862-1865
5. Everson W.V., Smart E.J. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med. 11:2001;246-250
6. Feron O., Belhassen L., Kobzik L., Smith T.W., Kelly R.A., Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem. 271:1996;22810-22814
7. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 49:2001;281-287
8. Brattstrom C., Wilczek H., Tyden G., Bottiger Y., Sawe J., Groth C.G. Hyperlipidemia in renal transplant recipients treated with sirolimus (RAPA). Transplantation. 65:1998;1272-1274
9. Feron O., Dessy C., Desager J.P., Balligand J.L. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 103:2001;113-118
10. Albrecht E.W., Stegeman C.A., Heeringa P., Henning R.H., van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol. 199:2003;8-17
11. Morrisett J.D., Abdel-Fattah G., Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 35:2003;143S-150S
12. Oemar B.S., Tschudi M.R., Godoy N., Brovkovich V., Malinski T., Luscher T.F. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 97:1998;2494-2498
13. von der Leyen H.E., Dzau V.J. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation. 103:2001;2760-2765
14. Feron O., Dessy C., Moniotte S., Desager J.P., Balligand J.L. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest. 103:1999;897-905
15. Kauser K., da Cunha V., Fitch R., Mallari C., Rubanyi G.M. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol. 278:2000;H1679-H1685
16. Minshall R.D., Sessa W.C., Stan R.V., Anderson R.G., Malik A.B. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol. 285:2003;L1179-L1183
17. Wang Y.X., Martin-McNulty B., Huw L.Y., da Cunha V., Post J., Hinchman J., et al. Anti-atherosclerotic effect of SMV depends on the presence of apolipoprotein E. Atherosclerosis. 162:2002;23-31
18. Davis M.E., Harrison D.G. Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation. 103:2001;2-4
19. Pham S.M., Shears L.L., Kawaharada N., Li S., Venkataramanan R., Sehgal S. High local production of nitric oxide as a possible mechanism by which RAPA prevents transplant arteriosclerosis. Transplant Proc. 30:1998;953-954